Repligen Corporation (NASDAQ:RGEN)‘s stock had its “hold” rating reaffirmed by analysts at Jefferies Group LLC in a report released on Thursday. They currently have a $40.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 5.49% from the company’s current price.

Several other research analysts also recently weighed in on RGEN. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Saturday, August 12th. TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. Stephens reiterated an “overweight” rating and issued a $50.00 price objective on shares of Repligen Corporation in a report on Tuesday, September 26th. Finally, First Analysis upgraded shares of Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Repligen Corporation has a consensus rating of “Buy” and a consensus price target of $45.40.

Repligen Corporation (NASDAQ RGEN) traded up 2.18% during midday trading on Thursday, reaching $37.92. The company’s stock had a trading volume of 367,742 shares. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 74.21 and a beta of 1.18. The stock’s 50 day moving average price is $40.45 and its 200-day moving average price is $39.77.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. During the same quarter in the prior year, the firm earned $0.16 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, analysts forecast that Repligen Corporation will post $0.59 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Repligen Corporation (RGEN) Rating Reiterated by Jefferies Group LLC” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/22/repligen-corporation-rgen-rating-reiterated-by-jefferies-group-llc.html.

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new stake in shares of Repligen Corporation in the 1st quarter valued at approximately $103,000. Victory Capital Management Inc. grew its stake in shares of Repligen Corporation by 76.6% in the 1st quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Repligen Corporation in the 2nd quarter valued at approximately $120,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Repligen Corporation in the 2nd quarter valued at approximately $123,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Repligen Corporation by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares during the period. 96.45% of the stock is owned by institutional investors and hedge funds.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.